96 results
8-K
EX-99.2
GLYC
GlycoMimetics Inc
6 May 24
Results of Operations and Financial Condition
4:01pm
between our expectations and actual results include unexpected safety or efficacy data, unexpected side effectsobserved during preclinical studies … ,R.T. Hoeg, A.S. Rosenberg, L. Molnar, A. Linh Dang-Chu, S.L. steward, and J.M. Tuscano, 2022 PublicationNumber: 2764 Encouraging safety and evidence
8-K
EX-99.1
GLYC
GlycoMimetics Inc
27 Mar 24
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
9:00am
and secondary endpoints of safety/tolerability and pharmacokinetics. There were no dose-limiting toxicities or other safety signals. Potentially
PRE 14A
vx5y0
22 Mar 24
Preliminary proxy
5:00pm
8-K
EX-99.1
x6usqxlzj sn
1 Mar 24
Regulation FD Disclosure
9:16am
8-K
EX-99.1
iokb7
3 Nov 23
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2023
8:35am
8-K
EX-99.1
elerv0i14oa 8vc3a3
2 Aug 23
GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2023
8:35am
8-K
EX-99.1
3m3pd
9 Nov 22
GlycoMimetics Reports Highlights and Financial Results for Third Quarter 2022
8:15am